Annual Information Update

Hikma Pharmaceuticals Plc 26 April 2006 Annual Information Update LONDON, 26 April 2006. In accordance with Prospectus Rule 5.2, Hikma Pharmaceuticals PLC ('Hikma' or 'the Company')(LSE: HIK) sets out below a summary of the information which has been published or made available to the public over the previous 12 months. The information referred to in this Update was up to date at the time the information was published, but some information may now be out of date. Stock Exchange announcements Announcements made by the Company via RNS, a Regulatory Information Service, may be viewed and downloaded from the London Stock Exchange website (www.londonstockexchange.com/marketnews) or from the press releases page on the Company's website at (http://investors.hikma.com/hikma/regulatorynews.jsp). The Stock Exchange announcements made during the defined period are: Date of announcement Headline of announcement 25 Apr 2006 Hikma to list Global Depository Receipts on DIFX 21 Apr 2006 Notification of Transaction 19 Apr 2006 Hikma acquires JPI 03 Apr 2006 Block listing 29 Mar 2006 Hikma Preliminary Results 25 Jan 2006 Hikma Announces FDA Approval 23 Jan 2006 Trading Statement 05 Dec 2005 Director/PDMR Shareholding 30 Nov 2005 Over allotment option 28 Nov 2005 Renewal of Contract 04 Nov 2005 Director/PDMR Shareholding 02 Nov 2005 Publication of Prospectus 01 Nov 2005 Stabilisation Notice 01 Nov 2005 Pricing Announcement 17 Oct 2005 Hikma Pharmaceutials announces intention to float Documents filed with the Financial Services Authority The company has filed the following documents with the Financial Services Authority ('FSA') over the previous 12 months. These documents are or will be available to be viewed via the FSA's Document Viewing Facility or at the Company's registered office. Date filed with the FSA Document filed with the FSA 26 Apr 2006 Annual report and accounts 26 Apr 2006 Notice of Annual General Meeting 01 Nov 2005 Prospectus Documents filed with Companies House The Company has made the following filings with Companies House. Copies of these documents may be obtained from Companies House, Crown Way, Maindy, Cardiff CF14 3UZ or, if you are a registered user, they may be viewed and downloaded using Companies House Direct at www.direct.companieshouse.gov.uk. The Companies House filings made during the defined period are: Date filed with Document filed with Companies House Companies House 26 Apr 2006 2005 Annual report and accounts 26 Apr 2006 Notice of Annual General Meeting 13 Feb 2006 Form 123 - Notice of increase in share capital 13 Feb 2006 Form 122 - Notice of sub-division 13 Feb 2006 Authorisation of allotment of securities 17 Jan 2006 Form 288a - Director appointed 29 Nov 2005 Form 288a - Director appointed 29 Nov 2005 Form 288a - Director appointed 29 Nov 2005 Form 288a - Director appointed 07 Nov 2005 Adoption of Memorandum of Association and Articles of Association 28 Oct 2005 Company name change 23 Sep 2005 Approval of change of rights of all shares 23 Sep 2005 Memorandum of Association and Articles of Association 19 Sep 2005 Company name change 22 Sep 2005 Form 288a - Director appointed 22 Sep 2005 Form 288a - Secretary appointed 22 Sep 2005 Form 288a - Director appointed 22 Sep 2005 Form 288a - Director resigned; Secretary resigned 22 Sep 2005 Form 288a - Director resigned 22 Sep 2005 Form 225 - Change of accounting reference date 16 Sep 2005 Authorisation to commence business and borrow 16 Sep 2005 Form 117 - Application to commence business 08 Sep 2005 Incorporation documents In addition, the Company filed Forms 88(2) - Return of Allotment of Shares with Companies House. These were posted on the Companies House Direct website on 13 February 2006 and 22 September. Henry Knowles Company Secretary 27 April 2006 - ENDS - Enquiries: Hikma Pharmaceuticals plc +44 20 7479 4870 Henry Knowles, Company Secretary +44 20 7479 4893 Susan Ringdal, Investor Relations Director Brunswick Group LLP +44 20 7404 5959 Jon Coles / Wendel Verbeek / Justine McIlroy / Alex Tweed Notes to Editors About Hikma Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products. Hikma's operations are conducted through three businesses: Generic, Branded and Injectable Pharmaceuticals. Hikma's operations are based principally in the United States, the Middle East and North Africa ('MENA') region and Europe. In 2005, the Group had revenue of $262 million and profit attributable to shareholders of $44 million. At 31 December 2005, the Group had over 1,800 employees. For news and other information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock Exchange
UK 100

Latest directors dealings